Woolworths Edges Toward 52-Week High as Investors Eye Grocery Recovery

Woolworths Edges Toward 52-Week High as Investors Eye Grocery Recovery

June 14, 2026

Sydney, June 15, 2026, 04:02 (AEST) —

  • Woolworths Group closed up 0.63% at A$38.33. Shares hit A$38.50, matching the high for the past year.
  • S&P/ASX 200 added 1.98% Friday. Consumer staples saw a 7.5% lift this week, pushing up defensive stocks like supermarkets.
  • Woolworths’ next big catalyst is its F26 full-year results, due out August 26, 2026.

c shares are trading just below a one-year top going into the new week, last changing hands at A$38.33 after rising 0.63% in recent ASX action. That rise caps a brisk rebound, with Intelligent Investor data showing the stock 8.71% above last week’s close. Investing.com put the day’s range between A$38.09 and A$38.50. A “52-week high” tracks the highest price in the past year, and Woolworths hit an intraday peak of A$38.50. Investors seem willing to pay more as the turnaround takes hold. Intelligent Investor

Woolworths shares rallied without a new price-sensitive announcement from the company. The latest filing on the ASX website is a director-interest notice from June 5, and the most recent price-sensitive release listed is the April 30 third-quarter sales update. That points to market rotation, valuation, and hopes for an earnings recovery driving the move, rather than anything new disclosed by Woolworths.

Australian stocks closed sharply higher Friday, tracking global relief as Middle East tensions appeared to cool. The S&P/ASX 200 climbed 170.8 points, or 1.98%, to 8,804. Consumer staples jumped 7.5% for the week, Morningstar/AAP said, giving a tailwind to Woolworths. Supermarkets, seen as defensive stocks, tend to keep steady sales when households cut back.

Bullish investors are focused on rising sales in Woolworths’ main Australian Food unit. In an update on April 30, the company posted a 4.5% lift in third-quarter group sales to A$18.1 billion. Australian Food was up 5.9%. Group eCommerce sales pushed 20.2% higher to A$2.7 billion. Chief executive Amanda Bardwell said, “Looking ahead, the conflict in the Middle East is creating greater uncertainty for our customers, suppliers and team,” as investors look for sales momentum to handle ongoing cost pressure.

The bear argument is that the rebound is baked in. Google Finance data showed 11 analysts recently, with four rating the stock a buy and seven at hold—none at sell. The average 12-month price target came in at A$35.13, under the current A$38.33. Price targets reflect where analysts see fair value in a year. When the average is under the market price, that points to little obvious upside unless forecasts get better.

Margin pressure is the big risk. Woolworths said it still expects F26 Australian Food EBIT growth in the mid- to high-single-digit range but not at the upper end anymore. EBIT, or earnings before interest and tax, is a standard way to measure operating profit. The company cited direct fuel cost exposure in the fourth quarter and spending on customer support, like its Price Freeze program. New Zealand Food is seeing slower market growth, higher fuel costs and some disruption from a new store operating model.

Woolworths isn’t looking cheap now, more fairly priced to a bit risky. The stock has defensive qualities, eCommerce momentum and better Australian Food sales. But shares are near their 52-week high, above the average analyst target. Risks like fuel, inflation, cautious shoppers and execution in New Zealand are still in play. The next big test is the full-year result on August 26. Investors will look for proof that sales growth is turning into operating profit, not just market share bought with higher prices.

Stock Market Today

  • Telix Pharmaceuticals Stock Rises Ahead of Inclusion in STOXX Health Care Indices and Upcoming FDA Decisions
    June 14, 2026, 1:57 PM EDT. Telix Pharmaceuticals shares increased 0.97% to A$13.60 on June 15, 2026, as the company prepared for inclusion in the STOXX Asia/Pacific 600 Health Care and STOXX Global 1800 Health Care indices effective June 22. This index addition may attract passive investment but does not alter Telix's fundamentals. Regulatory catalysts loom, with the FDA action date for Pixclara set for September 11 and a Zircaix resubmission planned for H1 2026. Telix, specializing in radiopharmaceutical theranostics, posted a 11% revenue rise to US$230 million in Q1 2026 and maintains revenue guidance near US$950 million. Clinical progress in prostate cancer trials supports bullish sentiment amid a 45% year-on-year share price decline.